Home » UCB Pharma Says Wilex to Acquire Oncology Portfolio
UCB Pharma Says Wilex to Acquire Oncology Portfolio
Belgium pharmaceutical UCB Pharma said that it has signed a deal with Germany’s Wilex, under which Wilex will acquire the rights to develop UCB’s preclinical oncology portfolio.
Fox Business
Fox Business
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May